RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
あれまあ。それは大変だ。
Fantastic work. Congrats!
RT @organischchemie: https://t.co/Sskakuxjex あるタンパク質Aが癌細胞で過剰 →このAを標的に薬Xを開発!承認! →タンパク質Aをクリスパーでノックアウト →癌はなぜか増殖し続ける →薬XをAをノックアウトした細胞に投与…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
分子標的薬のオフターゲットについて。遺伝子編集で突き止める。 Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials | Science Translational Medicine https://t.co/O7TwVuODmw
RT @zakkohane: Cancer drug targets are frequently not what we think they are. Well demonstrated by #CRISPR screens in this @sciencetm repor…
RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
RT @zakkohane: Cancer drug targets are frequently not what we think they are. Well demonstrated by #CRISPR screens in this @sciencetm repor…
RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
以前から言われてたけど、作用機序は説明されてたのとは違うけど、OTS167と964は効きそうなんですよね (;´Д`) #OTS https://t.co/N73MmEVsnk
RT @AUrbanucci: Here what happens when #pharma tells you #sorry : there is no money for mechanistic insights, we have already a #clinicaltr…
Here what happens when #pharma tells you #sorry : there is no money for mechanistic insights, we have already a #clinicaltrial ongoing :-) https://t.co/Q0bzB0NFAB
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @splon: Succinct thread describing important new study on how wrong we are about many anti-cancer drug targets. https://t.co/FJqhCiM1Fb
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials https://t.co/d3gWFcgANK
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
Very interesting paper on cancer drug off-target toxicity as a common mechanism of action https://t.co/OobaKxvB4j
RT @EricTopol: 97% of #cancer drugs tested fail. Why? When @carlzimmer is on-target about off-target cancer drugs, as determined by #CRISPR…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
Your Cancer Targets May Not Be Real https://t.co/L9NJWRZ6WH Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials https://t.co/klO97X0e0g
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
Factors contributing to the failure of many cancer drug clinical trials: https://t.co/6wOCGlumpL #cancerresearch #supportscience #endcancer
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
Off-target #toxicity is a common mechanism of action of #cancer #drugs undergoing clinical trials https://t.co/r9NbwayyAt
Really a nice narrative to help shift the focus of validating drug effects esp. a call to validate this kind of off-targets in PDX models and in vivo CRISPR screens.
RT @hilseth_mistrov: This sums up small molecules in Oncology quite well "Off-target toxicity drives efficacy": https://t.co/CGGNVuIkkD Bri…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @dhjutsw1: ICYMI: Some cancer drugs “work” because they don’t work the way we think they work. Who knew? @UTSWIMchief @UTSWInternalMed @…
RT @btnaughton: What does it mean if twitter threads communicate results more efficiently than a publication can? Do we need another kind o…
Cancer drugs don't always work as intended, researchers warn. https://t.co/PBiE6osPIJ https://t.co/IZCPiRv5WQ
RT @hilseth_mistrov: This sums up small molecules in Oncology quite well "Off-target toxicity drives efficacy": https://t.co/CGGNVuIkkD Bri…
RT @organischchemie: https://t.co/Sskakuxjex あるタンパク質Aが癌細胞で過剰 →このAを標的に薬Xを開発!承認! →タンパク質Aをクリスパーでノックアウト →癌はなぜか増殖し続ける →薬XをAをノックアウトした細胞に投与…
RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
How targeted are targeted therapies really? Some cancer drugs might not work the way we we thought they would. Interesting study (although not without limitations) https://t.co/NxOIQV9lZh
What a fantastic twitter thread!
there are some jaw-dropping moments in this thread. don't let the molecular bio jargon slow you down, and I think many questions are asked and answered in the comments
RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
The definitive example of how to tweet your work. Also, really exciting science.
RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. https://t.co/DlZHhuddrv
RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
Drugs may not do what we think they do https://t.co/gMN7G0c2gD
RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
RT @JSheltzer: Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of…
Our paper on off-target toxicity of anti-cancer drugs generated a lot of really great discussion! I wanted to answer some of the questions that people were asking in one place, and highlight some areas where I think that there’s more to learn.
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials https://t.co/mtymFRxZXz
This video is mesmerizing. Never ceases to amaze me. Also this result is kind of expected. Dirty drugs work. Someone call Mike Rowe to do a new show.
RT @NatureBiotech: Off-target toxicity might play an important role in efficacy of cancer drugs https://t.co/J8Z9FtKv7q #NBThighlight
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @ScienceTM: Multiple #cancer drug candidates in clinical trials kill tumor cells through off-target effects instead of by interacting wi…
Multiple #cancer drug candidates in clinical trials kill tumor cells through off-target effects instead of by interacting with their intended molecular targets, a new study shows. @CSHL #PreClinicalTesting https://t.co/e8Qo6gUp63 https://t.co/gWJtRnZ8Ua
RT @organischchemie: https://t.co/Sskakuxjex あるタンパク質Aが癌細胞で過剰 →このAを標的に薬Xを開発!承認! →タンパク質Aをクリスパーでノックアウト →癌はなぜか増殖し続ける →薬XをAをノックアウトした細胞に投与…
No intelligent person on Earth can convince a vax-pusher to stop and look at the experimental evidence. Same with most cancer researchers. But see: https://t.co/NteUOc3iON and watch the vax-pushers lose at the same time as Big Pharma loses appeal for their
RT @organischchemie: https://t.co/Sskakuxjex あるタンパク質Aが癌細胞で過剰 →このAを標的に薬Xを開発!承認! →タンパク質Aをクリスパーでノックアウト →癌はなぜか増殖し続ける →薬XをAをノックアウトした細胞に投与…
RT @Behrouzh_H: Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials https://t.co/Czs2q8iOyx
RT @organischchemie: https://t.co/Sskakuxjex あるタンパク質Aが癌細胞で過剰 →このAを標的に薬Xを開発!承認! →タンパク質Aをクリスパーでノックアウト →癌はなぜか増殖し続ける →薬XをAをノックアウトした細胞に投与…
Wow...very cool genetic approaches to identify true targets of cancer drugs and identify mechanisms of action. Read the whole thread.
RT @NCIgenomics: A CRISPR-Cas9 mutagenesis study suggests many cancer drugs and drug targets may not do what we think they do https://t.co/…
Stringent testing of anti cancer drugs is needed to help predict the rate of clinical trial failures/ potential successes early on. #clinicaltrials #CancerResearch
RT @organischchemie: https://t.co/Sskakuxjex あるタンパク質Aが癌細胞で過剰 →このAを標的に薬Xを開発!承認! →タンパク質Aをクリスパーでノックアウト →癌はなぜか増殖し続ける →薬XをAをノックアウトした細胞に投与…
RT @organischchemie: https://t.co/Sskakuxjex あるタンパク質Aが癌細胞で過剰 →このAを標的に薬Xを開発!承認! →タンパク質Aをクリスパーでノックアウト →癌はなぜか増殖し続ける →薬XをAをノックアウトした細胞に投与…
RT @NatureBiotech: Off-target toxicity might play an important role in efficacy of cancer drugs https://t.co/J8Z9FtKv7q #NBThighlight
RT @NCIgenomics: A CRISPR-Cas9 mutagenesis study suggests many cancer drugs and drug targets may not do what we think they do https://t.co/…
RT @organischchemie: https://t.co/Sskakuxjex あるタンパク質Aが癌細胞で過剰 →このAを標的に薬Xを開発!承認! →タンパク質Aをクリスパーでノックアウト →癌はなぜか増殖し続ける →薬XをAをノックアウトした細胞に投与…
This really is a pretty great result: https://t.co/caFmffWIoC
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. | Science Translational Medicine | https://t.co/3uiQ52bW9k
RT @NatureBiotech: Off-target toxicity might play an important role in efficacy of cancer drugs https://t.co/J8Z9FtKv7q #NBThighlight
RT @NatureBiotech: Off-target toxicity might play an important role in efficacy of cancer drugs https://t.co/J8Z9FtKv7q #NBThighlight
RT @wintonARK: Using crispr it becomes clear that a supermajority of cancer drugs developed through 2015 essentially work by accident. In…
RT @kb_mccauley: This is a really cool study! Seems like big implications for many drugs in the pipeline... https://t.co/y1hbuqzOeG
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
RT @JSheltzer: Our new paper is out today. We used CRISPR to uncover some really striking findings with several drugs and drug targets in c…
As much as cancer nano field is now getting sharply focused to address delivery challenges to tumors. The drugs they deliver are no less problematic.
RT @CSHL: CSHL Fellow Jason Sheltzer and his colleagues are rocking the medical news headlines with their latest results. If you're intere…
RT @organischchemie: https://t.co/Sskakuxjex あるタンパク質Aが癌細胞で過剰 →このAを標的に薬Xを開発!承認! →タンパク質Aをクリスパーでノックアウト →癌はなぜか増殖し続ける →薬XをAをノックアウトした細胞に投与…
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials | Science Translational Medicine https://t.co/q5ITj3GqVt